UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | |
Date of Report (Date of Earliest Event Reported): | | May 15, 2015 |
Hansen Medical, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | |
Delaware | 001-33151 | 14-1850535 |
_____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
| | |
800 East Middlefield Road, Mountain View, California | | 94043 |
_________________________________ (Address of principal executive offices) | | ___________ (Zip Code) |
| | |
Registrant’s telephone number, including area code: | | (650) 404-5800 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 14, 2015, Hansen Medical, Inc. ("Hansen") announced that Hansen's Magellan™ 10Fr Robotic Catheter received European Conformity (CE) Marking for use in the peripheral vasculature. Hansen's 10-Q filed on May 11, 2015 incorrectly noted that the Magellan™ 10Fr Robotic Catheter received FDA approval. Hansen is still in the process of obtaining FDA approval for the Magellan™ 10Fr Robotic Catheter.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | Hansen Medical, Inc. |
| | | | |
May 15, 2015 | | By: | | /s/ Christopher P. Lowe
|
| | | |
|
| | | | Name: Christopher P. Lowe |
| | | | Title: Interim Chief Financial Officer |